CD3/CD19 negative allogeneic hematopoietic stem cells (University of Pittsburgh)

N/A

Report date: 2023/01/12 15:52:24

Base Information

Drug NameCD3/CD19 negative allogeneic hematopoietic stem cells (University of Pittsburgh)
Drug Alias NameCD3/CD19阴性异基因造血干细胞
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsImmunologic Deficiency SyndromesJob SyndromeGranulomatous Disease, Chronic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pittsburgh
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Pittsburgh
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesJob SyndromeGranulomatous Disease, Chronic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A